The Relative Strength (RS) Rating for McKesson stock jumped into a new percentile Wednesday, as it got a lift from 70 to 75.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 as they begin their biggest runs. See if McKesson stock can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Is McKesson Stock A Buy?
McKesson stock is trying to complete a cup without handle with a 637.51 buy point. See if it medical stock can break out in heavy trading.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 13%, compared to 8% in the prior report. Revenue increased from 6% to 21%.
McKesson stock holds the No. 3 rank among its peers in the Medical-Wholesale Drugs industry group. Cencora is the top-ranked stock within the group.
